06-Mar-2014 - A GSK-led consortium will develop manufacturing technologies in a Government-backed scheme intended to safeguard the UK drug production sector.
06-Mar-2014 - Boehringer Ingelheim says it will pump a further €330m ($453m) into a German manufacturing facility critised by the US FDA in its rejection of the drug empagliflozin.
06-Mar-2014 - The US FDA has released draft guidance on how post-approval manufacturing changes should be reported in annual reports.
04-Mar-2014 - Eli Lilly says investment in its Sao Paolo, Brazil packaging plant will support growth for the local market.
04-Mar-2014 - The European Medicines Agency (EMA) stressed the potential benefits of continuous process validation in guidance issued this week and underlined that data submitted by drugmakers must demonstrate the adequacy of production operations at each site.
03-Mar-2014 - Bayer has predicted double digit growth in its Chinese consumer health business as it acquires OTC firm Dihon Pharmaceutical Group.
27-Feb-2014 - Novartis says it will continue to spend around $1m a week on clinical trials in the UK after its R&D site closes in June.
27-Feb-2014 - National prioritization, investments in healthcare infrastructure and building better epidemiological and cost databases could bring more innovative medicines to middle-income countries, according to an independent study conducted by Charles River Associates.
26-Feb-2014 - Pfizer says its hypothyroid drug Levoxyl will be available within a week after a musty smell coming from the oxygen-absorbing canister stopped production last February.
24-Feb-2014 - Development of a new quality "super office" was motivated by a desire to simplify oversight and is not a response to the recent spate of problems at overseas suppliers, says the US FDA.
24-Feb-2014 - Simon Sturge leaves Boehringer Ingelheim to head Merck's biosimilars unit, as well as the European Medicines Agency, Shire and EFPIA in this week's People on the Move column.
20-Feb-2014 - A longer than expected upgrade to one of its injectable plants has caused Pfizer to announce that there is a shortage of methylprednisolone sodium succinate injections.
13-Feb-2014 - The US FDA has upgraded Hospira’s troubled Rocky Mount, North Carolina plant to VAI (voluntary action indicated) status though its 2010 Warning Letter still stands.
12-Feb-2014 - Jazz Pharmaceuticals has begun construction on a manufacturing facility in Ireland a month after acquiring a late stage narcoleptic compound.
10-Feb-2014 - Pfizer says its ‘off the shelf’ aseptic processing capacity is shifting the paradigm of pharma manufacturing, with emerging markets and personalised medicine driving the change.
03-Feb-2014 - Novartis has confirmed that pharma jobs will be reallocated in 2014 in a continuation of the productivity drive that saved the firm $2.8bn (EUR2bn) last year.
31-Jan-2014 - Shipments of chicken pox vaccines from a troubled Belgian facility should recommence in early Q2 2014, says GSK, though the root cause of the manufacturing issues are still unknown.
30-Jan-2014 - CordenPharma has received certification of Potent Compound Safety at a US plant and joins a growing list of drugmakers looking to assure HPAPI safety, according to SafeBridge Consultants.
23-Jan-2014 - Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
22-Jan-2014 - Novartis says it intends to shutter a New York manufacturing site due to reduced demand following the loss of exclusivity on its one-time topseller Diovan.
21-Jan-2014 - Efforts to address the current shortage of IV fluids in the US are a placing a strain on manufacturing capabilities according to Baxter, which is investing to try and increase production capacity.
15-Jan-2014 - The combination cholesterol drug Liptruzet will be unavailable in the US for the foreseeable future, says Merck & Co., after packaging defect at CMO led to a total product recall.
15-Jan-2014 - Chinese authorities have given Thermo Fisher Scientific the green light to buy Life Technologies on the condition it discounts certain products sold in the coutry.
15-Jan-2014 - Genentech has resolved the issues that earned its Herceptin API plant in Vacaville, California a Form 483 from the US FDA last year.
14-Jan-2014 - Merck & Co.’s divestiture of its RNA interference business (RNAi) was part of a strategy to cut $2.5bn and focus on core areas, according to its CEO.
A longer than expected upgrade to one of its injectable plants has caused Pfizer to announce that...
Despite splintering into rival companies a century ago, Merck & Co. and Merck KGaA have once again...
Sinopharm expects customer drug launches and its recent investment in cancer injectables to drive revenue gains and...
The US FDA has upgraded Hospira’s troubled Rocky Mount, North Carolina plant to VAI (voluntary action indicated)...
It is too early to predict what impact proposed changes to US rules on chemical plant security...
Pfizer says its ‘off the shelf’ aseptic processing capacity is shifting the paradigm of pharma manufacturing, with...